BullFrog AI Holdings, Inc.

BullFrog AI Holdings, Inc. is a digital biopharmaceutical company headquartered in Gaithersburg, Maryland, focused on leveraging artificial intelligence (AI) and machine learning (ML) to transform drug discovery and development. The company's mission is to improve patient outcomes by identifying precise connections between therapies and highly responsive patients, aiming to reduce the time and cost associated with traditional drug development processes.

The company offers a suite of proprietary AI/ML platforms, including bfLEAP®, an explainable AI platform for uncovering hidden relationships in complex data; bfPREP™, a data harmonization tool that transforms fragmented biomedical data into AI-ready assets; and bfARENAS™, a scenario-based decision engine for optimizing R&D portfolios. These platforms are designed to accelerate target identification, optimize clinical trials, and enable patient stratification across various market segments, including oncology, neuroscience, and rare diseases.

In recent news, BullFrog AI Holdings, Inc. announced a commercial agreement on March 30, 2026, with a top 5 global pharmaceutical company to utilize its bfLEAP® platform for identifying drug targets in Major Depressive Disorder. The company also launched its bfARENAS™ platform in March 2026, completing its end-to-end AI stack for pharmaceutical R&D. Led by Founder, Chairman, and CEO Vininder (Vin) Singh, and with Josh Blacher appointed as CFO in December 2024, BullFrog AI has secured funding into late 2027 and regained compliance with Nasdaq's shareholders' equity requirement as of April 22, 2026, positioning itself for continued commercial expansion.